Neurofibromatosis type 2 : The Lancet
Links shared publicly online about this topic.
- 2,001total visits
Neurofibromatosis type 2 : The Lancet
View full resource at thelancet.com
Tags: Doctor
Most Recently Shared on June 1, 2009 at 4:22 pm By:
Always necessary review (especially for Med-Peds guys like me) - Neurofibromatosis - http://bit.ly/19X7Tr
BMC Medical Genetics | Abstract | Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review o
biomedcentral.com — “Pierre-Robin sequence (PRS) is defined by micro- and/or retrognathia, glossoptosis and cleft soft palate, either caused by deformational defect or part of a malformation syndrome. Neurofibromatosis type 2 (NF2) is an autosomal dominant syndrome caused by mutations in the NF2 gene on chromosome 22q12.2. NF2 is characterized by bilateral vestibular schwannomas, spinal cord schwannomas, meningiomas and ependymomas, and juvenile cataracts. To date, NF2 and PRS have not been described together in the” View full resource at biomedcentral.com
Most Recently Shared on March 22, 2012 at 4:59 am By:
Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child ... http://t.co/1G2H2hVW
Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial : The Lancet Infectious Diseases
thelancet.com — “Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. By...” View full resource at thelancet.com
Most Recently Shared on March 19, 2012 at 4:29 pm By:
Safe low cost approaches to delay HIV progression are needed. Study looks at aciclovir for HIV & HSV dual infection http://t.co/fFPu4gPx
Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial : The Lancet Infectious Diseases
thelancet.com — “Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial. By...” View full resource at thelancet.com
Most Recently Shared on March 19, 2012 at 12:28 pm By:
Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and... http://t.co/dfiK8Piq
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy : The Lancet Neurology
thelancet.com — “Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. By - Dr Lenore J Launer PhD, Michael E Miller P...” View full resource at thelancet.com
Most Recently Shared on September 27, 2011 at 10:35 pm By:
Intensively reducing blood sugar does not necessarily help slow cognitive decline in diabetes http://t.co/ygjcAYJi #Neurology
Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial : The Lancet
instapaper.com — “Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial : The Lancet” View full resource at instapaper.com
Most Recently Shared on July 13, 2011 at 6:26 pm By:
Yvo Sijpkens MD Physician, Doctor, Internist, and Nephrologist
An intensive diet intervention soon after diagnosis of #diabetes can improve glycaemic control.: http://t.co/4rbWKLa
Endocrinology Article | Diabetes Mellitus, Type 2
mdlinx.com — “Management of type 2 diabetes: new and future developments in treatment” View full resource at mdlinx.com
Most Recently Shared on June 28, 2011 at 12:07 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Management of type 2 diabetes: new and future developments in treatment: The Lancet - Early Online Publication http://bit.ly/jFQIGQ #endo
Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial : The Lancet
thelancet.com — “Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial. By - Dr RC Andrews PhD, AR Cooper PhD, AA Montgo...” View full resource at thelancet.com
Most Recently Shared on June 27, 2011 at 11:09 pm By:
Symposier Endocrino Health Site
Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes http://bit.ly/iK1iX5
Study: Diabetes Rate Doubles Worldwide - FoxNews.com
foxnews.com — “The number of adults suffering from Type 2 diabetes has more than doubled across the globe in the past 30 years, according to a study published in The Lancet” View full resource at foxnews.com
Most Recently Shared on June 27, 2011 at 3:03 pm By:
Study: Diabetes Rate Doubles Worldwide: The number of adults suffering from Type 2 diabetes has more than double... http://fxn.ws/l8KcEW
Vascular aspects of multiple sclerosis : The Lancet Neurology
thelancet.com — “Vascular aspects of multiple sclerosis. By - Dr Miguel D'haeseleer MD, Melissa Cambron MD, Ludo Vanopdenbosch MD, Prof Jacques De Keyser MD” View full resource at thelancet.com
Most Recently Shared on June 19, 2011 at 8:18 am By:
[Review] Vascular aspects of multiple sclerosis: SummaryThree types of vascular dysfunction have been described ... http://bit.ly/ko2Rve
Following A Path To A Potential Therapy For NF2, A Rare Tumor Disorder
medicalnewstoday.com — “The proteins that provide cells with a sense of personal space could lead to a therapeutic target for Neurofibromatosis Type 2 (NF2), an inherited cancer disorder, according to researchers at The” View full resource at medicalnewstoday.com
Most Recently Shared on April 16, 2011 at 8:05 am By:
Following A Path To A Potential Therapy For NF2, A Rare Tumor Disorder http://mnt.to/3TKd #genetics
Proteins could lead to new therapeutic target for NF2: Wistar Institute researchers
news-medical.net — “The proteins that provide cells with a sense of personal space could lead to a therapeutic target for Neurofibromatosis Type 2, an inherited cancer disorder, according to researchers at The Wistar Institute. Their findings, which appear in the April 12 issue of the journal Cancer Cell, could have profound implications for NF2 and related cancers, such as mesothelioma.” View full resource at news-medical.net
Most Recently Shared on April 16, 2011 at 4:49 am By:
Lung Cancer News: Proteins could lead to new therapeutic target for NF2: Wistar Institute researchers: The prote... http://bit.ly/gg8bZ5
Researchers follow a path to a potential therapy for NF2, a rare tumor disorder
physorg.com — “The proteins that provide cells with a sense of personal space could lead to a therapeutic target for Neurofibromatosis Type 2 (NF2), an inherited cancer disorder, according to researchers at The Wistar Institute. Their findings, which appear in the April 12 issue of the journal Cancer Cell, could have ...” View full resource at physorg.com
Most Recently Shared on April 15, 2011 at 7:18 pm By:
Researchers follow a path to a potential therapy for NF2, a rare tumor disorder http://bit.ly/fR45jQ
New medication may help obese people at risk for type 2 diabetes lose weight
endocrineweb.com — “An experimental combination of drugs may result in unprecedented weight loss and dramatic improvements in metabolic risk factors among obese individuals who are in jeopardy of developing type 2 diabetes, according to a new study from a team of Duke University researchers.The group reported in the journal The Lancet that a combination of the obesity” View full resource at endocrineweb.com
Most Recently Shared on April 12, 2011 at 11:40 pm By:
New medication may help obese people at risk for type 2 diabetes lose weight: An experimental combination of dru... http://bit.ly/i8y1a1
Study: Long-acting insulin is effective for Type 2 diabetes - Related Stories - DiabetesPro SmartBrief
smartbrief.com — “Patients with Type 2 diabetes who received once-daily or thrice-a-week injections of long-acting insulin degludec had stable blood glucose levels similar to those given daily shots of insulin glargine, a study in The Lancet showed. "Doses given three times a week might improve adherence and cause l--” View full resource at smartbrief.com
Most Recently Shared on March 10, 2011 at 5:55 pm By:
Study: Long-acting insulin is effective for Type 2 diabetes http://sbne.ws/r/6Y3B
Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial : The Lancet
thelancet.com — “Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase ...” View full resource at thelancet.com
Most Recently Shared on March 10, 2011 at 10:27 am By:
Insulin degludec once a day or three times a week compared with insulin glargine once a day http://fb.thelancet.com/JSY #diabetes
Advertisement
